Category: Therapeutics/pharmacology

T.68 - Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of sel-212 Indicates That the Addition of Tolerogenic Nanoparticles to Pegylated Uricase Enables Sustained Control of Serum Uric Acid in Symptomatic Gout Patients

Thursday, Jun 15
5:45 PM – 7:00 PM

Lloyd Johnston

COO
Selecta Biosciences
Watertown, Massachusetts

Takashi KEI.. Kishimoto

Chief Scientific Officer
Selecta Biosciences
Watertown, Massachusetts

Alan Kivitz

Altoona Center for Clinical Research
Altoona, Pennsylvania

Earl Sands

Chief Medical Officer
Selecta Biosciences
Watertown, Massachusetts